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Aim: Left ventricular non-compaction (LVNC) is perceived as a rare high-risk
cardiomyopathy characterized by excess left ventricular (LV) trabeculation. However,
there is increasing evidence contesting the clinical significance of LV hyper-trabeculation
and the existence of LVNC as a distinct cardiomyopathy. The aim of this study is to assess
the association of LV trabeculation extent with cardiovascular morbidity and all-cause
mortality in patients undergoing clinical cardiac magnetic resonance (CMR) scans across
57 European centers from the EuroCMR registry.
Methods and Results: We studied 822 randomly selected cases from the EuroCMR
registry. Image acquisition was according to international guidelines. We manually
segmented images for LV chamber quantification and measurement of LV trabeculation
(as per Petersen criteria). We report the association between LV trabeculation extent
and important cardiovascular morbidities (stroke, atrial fibrillation, heart failure) and
all-cause mortality prospectively recorded over 404 ± 82 days of follow-up. Maximal
non-compaction to compaction ratio (NC/C) was mean (standard deviation) 1.81
± 0.67, from these, 17% were above the threshold for hyper-trabeculation (NC/C
> 2.3). LV trabeculation extent was not associated with increased risk of the
defined outcomes (morbidities, mortality, LV CMR indices) in the whole cohort, or in
sub-analyses of individuals without ischaemic heart disease, or those with NC/C > 2.3.
Zemrak et al. LV Hypertrabeculation and Cardiovascular Outcomes
Conclusion: Among 882 patients undergoing clinical CMR, excess LV trabeculation
was not associated with a range of important cardiovascular morbidities or all-cause
mortality over ∼12 months of prospective follow-up. These findings suggest that LV
hyper-trabeculation alone is not an indicator for worse cardiovascular prognosis.
Keywords: left ventricular non-compaction, left ventricular trabeculation, cardiomyopathy, cardiac magnetic
resonance, mortality
INTRODUCTION
Left ventricular non-compaction cardiomyopathy (LVNC) is
perceived as a rare genetic cardiomyopathy characterized
by abnormal arrest of in-utero myocardial compaction (1).
Tertiary center cohorts of LVNC report association with life-
threatening arrhythmias, thromboembolism, and left ventricular
(LV) dysfunction (2–5). LVNC is recognized as a “genetic
cardiomyopathy” by the American Heart Association and as
an “unclassified cardiomyopathy” by the European Society of
Cardiology (6, 7). Identification of excess LV trabeculations
alongside a thin layer of compacted myocardium on non-
invasive imaging is key to diagnosis. The Petersen cardiac
magnetic resonance (CMR) criteria are widely used for
quantification of LV trabeculations and to guide diagnosis of
LVNC (8).
Increased awareness of LVNC and improved imaging
techniques have led to a surge in its diagnosis. However,
studies of healthy cohorts have identified fulfillment of the
LVNC imaging criteria in a high proportion of individuals
with no clear association to adverse outcomes (9–11).
Similar findings have been reported in small studies of
asymptomatic athletes and healthy pregnant women (12–
14). These findings have been replicated in single center
studies of symptomatic individuals and those with known
structural heart disease (15, 16). Further, a multicenter study of
individuals diagnosed with LVNC reports better than expected
outcomes with no prognostic impact of LV trabeculation beyond
known parameters such as left ventricular ejection fraction
(LVEF) (17).
There is increasing uncertainty regarding the clinical
significance of LV hyper-trabeculation and some have questioned
the status of LVNC as a distinct cardiomyopathy (18). However,
many of these studies have been conducted in low-risk
populations, in whom application of diagnostic criteria
is misleading.
There remains some uncertainty regarding generalisability
of findings from these low-risk asymptomatic cohorts
to patients seen in clinical practice. It is important to
ascertain the significance of LV trabeculation in a real-
life population with clinical indication for CMR. We
present the first prospective multicenter multinational
study of the relationship of the extent of LV trabeculation
with cardiovascular morbidity and all-cause mortality




The EuroCMR registry was set up to assess the clinical
utility and prognostic impact of CMR in real-life clinical
scenarios. Over 37,000 consecutive patients undergoing routine
clinical CMR were recruited from 57 center in 15 European
countries (19). Scans were performed in compliance with
standardized protocols. The only exclusion criterion was
contraindication to CMR. There was prospective follow-up
of patients with suspected coronary artery disease (CAD)
or hypertrophic cardiomyopathy (HCM) through standardized
telephone interviews (Supplementary Table 1). If contact with
the patient was unsuccessful, government registration offices
were contacted to obtain updated contact information or details
of cause of death. The EuroCMR registry study design and
protocols are detailed elsewhere (20). All participating center had
approval from local institutional ethics review boards, and all
patients provided written informed consent in accordance to the
Declaration of Helsinki.
Selection of CMR Studies
In order to ensure quality control within the EuroCMR registry,
there was requirement for each center to submit a selection
of random cases for quality assessment. This created a bank
of 980 randomly selected scans collated from all participating
center. The current study is based on analysis of this sample.
All scans were anonymised, and the demographic and clinical
data were not available at the time of image analysis. After
quality control checks, 158 scans were excluded due to sub-
optimal image quality, the remaining 822 scans are included in
this analysis (Figure 1).
Measurement of LV Volumes and Function
CMR studies were analyzed using cvi42 software (Circle
Cardiovascular Imaging Inc, Calgary, Canada). Left ventricular
end diastolic volume (LVEDV), end systolic volume (LVESV),
and end-diastolic mass (LVM) were obtained from cine short-
axis images covering the LV from base to apex. End-systole
and end-diastole were defined by the cardiac phases with the
largest and smallest blood pool area at the mid-ventricular level.
The operator defined the slice range (base to apex). Endocardial
and epicardial contours were manually drawn at end-diastole
and end-systole for each slice according to expert consensus
recommendations (21). Papillary muscles were included in the
blood pool. The cvi42 software computed LV volumes by slice
summation, LVEF was calculated in the usual way. LVM was
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FIGURE 1 | Flow diagram of exclusion process from the initial unselected scans. IHD, ischaemic heart disease; LV, left ventricle; NC/C, non-compacted to compacted
ratio; SAX, short-axis stack.
calculated by subtracting LVESV from the epicardial volume in
end-diastole and multiplying it by the myocardial muscle density
of 1.05 g/ml. LV parameters were indexed to body surface area
(BSA, denoted by i).
Measurement of LV Trabeculations
Three long-axis (2-, 3-, and 4-chamber) cine images were used
for measuring the thickness of compacted myocardium and
trabeculations at the centre of 16 segments of the AHA model
(Figure 2). Compacted myocardium was defined as a myocardial
layer of homogeneous moderate signal intensity (SI) distinctly
separate from the blood pool. Trabeculations were defined as
a meshwork of moderate SI on the endocardial surface of the
compacted myocardium with interspersion of higher SI from
the blood pool (Figure 3). Papillary muscles were excluded from
measurements. Short-axis views were used in conjunction with
the long axis images to aid identification of papillary muscles. In
normal individuals, the true apex is typically thin with prominent
trabeculations, it was therefore also excluded from analysis.
The maximum ratio of non-compaction to compaction (NC/C)
was calculated for each segment. NC/C >2.3 was used as cut-
off for LVNC as per the Petersen criteria (8). Measurements
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FIGURE 2 | Measurement of NC/C ratios in EuroCMR Registry in 16 segments of the American Heart Association model excluding the true apical cap (segment 17).
(A) Four chambers view, (B) two chambers view, (C) three chambers view.
FIGURE 3 | Measurement of NC/C ratios in 4-chamber, 2-chamber, and 3-chamber longitudinal view. Red lines represent compacted myocardium defined as a
myocardial layer of homogeneous moderate signal intensity distinctly separate from the blood pool, yellow lines represent measurement of trabeculations defined as a
meshwork of moderate signal intensity on the endocardial surface of the compacted myocardium with interspersion of higher SI from the blood pool; NC/C,
non-compacted to compacted ratio. SI, signal intensity.
of 100 randomly selected studies repeated by the first reader
showed excellent intraobserver variability (intraclass correlation
coefficients (ICC): LVEDVi 0.98, LVESVi 0.95, LVEF 0.83, LVMi
0.97; p < 0.0001 for all parameters). The interobserver variability
in the same 100 studies of LVmeasurements in our group showed
very good to excellent reproducibility; ICC values: LVEDVi
0.97, LVESVi 0.88, LVEF 0.71, LVMi 0.92; p < 0.0001 for
all measurements.
Outcomes
We considered the following outcomes: all-cause mortality,
stroke, atrial fibrillation, severe heart failure (defined as New
York Heart Association class 3 and 4). Outcomes were
obtained from standardized EuroCMR interviews with follow
up duration of 404 ± 82 days. Additionally, we investigated the
association of demographic and baseline characteristics on LV
trabeculation extent.
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Statistical Analysis
Statistical analysis was performed using R version 3.6.1 (2019-07-
05) [R Core Team (2013). R: A language and environment for
statistical computing. R Foundation for Statistical Computing,
Vienna, Austria. URL: http://www.R-project.org/]. Continuous
variables are summarized with mean (standard deviation, SD)
or median (interquartile range, IQR). Categorical variables are
presented as frequencies and percentages. Differences between
LV trabeculation quintiles were evaluated by the analysis of
variance (ANOVA) with a post-hoc Tukey test for continuous
variables and chi-squared test for categorical variables. Univariate
linear regression models were used to assess the relationship
between demographic factors, clinical data and LV structural
parameters as exposure variables and maximal NC/C as the
outcome variable. Cox proportional hazards regression models
were used to estimate hazard ratios (HR) and the associated
95% confidence interval (CI) for mortality. Univariable logistic-
regression models were used to estimate the odds ratio (OR) and
the associated 95% CI for the endpoints. LV trabeculation may
be more relevant to individuals with suspected non-ischaemic
cardiomyopathies. Therefore, subgroup analysis was performed
on a subgroup of 569 subjects without ischaemic heart disease
(IHD), defined as having no history of myocardial infarction,
coronary revascularisation, or evidence of IHD on CMR.
RESULTS
Baseline Demographics and Indications for
CMR
Demographic data are presented in Table 1. Sixty three
percenatge (n = 516) of participants were male. Mean age was
59 ± 14 years (range: 16–90). There was substantial burden
of cardiovascular risk factors: hypertension 60%, diabetes 14%,
dyslipidaemia 40%, smoking history 29%. The most common
indications for CMR were evaluation of coronary artery disease
(81.9%), cardiomyopathy (15.7%), and myocarditis (8.5%), there
was non-exclusivity of indications.
Diagnoses Following CMR
No abnormality was detected in 49% of the CMR scans.
IHD was diagnosed in 25% of patients. Amongst these,
myocardial ischaemia was detected in 147 cases, syndrome X
in 64, and cardiac thrombus in one patient. Non-ischaemic
cardiomyopathies were diagnosed in 111 patients: HCM (n
= 59), dilated cardiomyopathy (n = 33), arrhythmogenic
right ventricular cardiomyopathy (n = 1), unclassified
cardiomyopathy (n = 18). Myocarditis was diagnosed in
29 patients.
LV Trabeculation Extent
NC/C was calculated in 10,456 (79.5%) segments. The remaining
2,696 segments either had insufficient contrast between the blood
pool and the myocardium or were off-axis impeding confident
measurement of NC/C. NC/C >2.3 was measured in at least
one segment for 17.2% of participants (n = 142), and in at
least two segments for 5.1% (n = 42). The maximal NC/C
had a log-normal distribution. The mean maximal NC/C for
each participant’s analyzed segments was 1.81 ± 0.67. Greater
magnitude of trabeculation was detected in lateral segments, and
increased from base to apex. LV trabeculation was not seen in the
basal infero-septal segment of any participant.
LV Volumes, Mass, and Systolic Function
LV volumes and functional parameters are presented in Table 1.
Severe LV systolic dysfunction (LVEF ≤35%) was detected in
5.6% (n= 46). There were no differences between the quintiles of
maximal NC/C in the frequency of severe LV systolic dysfunction
(p= 0.39).
Determinants of Maximal NC/C
NC/C was higher in women than in men (1.89 ± 0.72 vs. 1.77 ±
0.64, p < 0.05) and decreased with age (β = −0.05 per decade, p
< 0.01). Maximal NC/C was larger by 0.5 for every 100 ml/m2
increase in LVEDVi (p < 0.0001), and by 0.4 for every 100
ml/m2 increase in LVESVi (p < 0.0001). Maximal NC/C was
also larger by 0.06 units for every 10% decrease in LV ejection
fraction (p < 0.01).
Association of LV Trabeculation With
Mortality
Mortality data was available for 530 participants with mean
follow-up of 404 ± 82 days. During the follow up period, 10
deaths were recorded (death rate of 1.9%). The extent of maximal
NC/C was not associated with increased mortality. There was
no difference in survival between quintiles of maximal NC/C
(Table 2). Similarly, there was no excess mortality in those with
the highest NC/C (quintile 5, NC/C 2.23 to 5.64) compared
to the remaining participants (OR 0.51, 95% CI: 0.03–2.76, p-
value 0.53).
Association of LV Trabeculation With
Clinical Outcomes
Heart Failure
Data on heart failure status assessed by the New York
Heart Association (NYHA) classification was available for 513
participants. Of these, 65% (n = 333) were in NYHA class I,
11.7% (n = 60) in NYHA class II, 3.7% (n = 19) in NYHA
class III, and <1% (n = 5) in NYHA class IV. Increasing
quintiles of the maximal NC/C were not associated with greater
odds of severe heart failure defined as NYHA class III and IV
(Table 3). Sensitivity analyses looking at (1) Quintile 5 vs. the
remaining cohort, (2) LVNC >2.3, and (3) number of segments
with NC/C>2.3 showed similar results.
Stroke
Twenty-eight (3.4%) participants had prior history of stroke.
There were no differences in the prevalence of stroke between the
quintiles of maximal NC/C (p= 0.16) (Table 1). One participant
developed a stroke during follow-up. His maximal NC/C was
2.38. Inclusion of this case in the analysis did not alter the
results (Table 3).
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TABLE 1 | Summary of baseline demographic and selected cardiac magnetic resonance data.
All Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 p-value
NC/C 0.55–1.29 1.3–1.54 1.55–1.83 1.84–2.22 2.23–5.64
n 822 166 167 161 166 162
Baseline demographics and cardiovascular risk factors
Age (years) 59.4 ± 13.9 60.9 ± 13.8 59.7 ± 14.6 59.7 ± 13.9 60.5 ± 13.1 56.1 ± 13.8 <0.05
Females 306 (37.2%) 53 (31.9%) 57 (34.1%) 62 (38.5%) 62 (37.3%) 72 (44.4%) 0.18
Body mass index (kg/m2 ) 27.6 ± 5.9 28.0 ± 5.0 27.9 ± 7.3 26.6 ± 4.0 28.1 ± 6.8 27.1 ± 5.8 0.11
Height (cm) 172.2 ± 9.8 172.6 ± 9.5 172.4 ± 11.1 171.9 ± 9.3 172.1 ± 9.4 171.9 ± 9.8 0.96
Weight (kg) 81.8 ± 17.3 83.5 ± 16.5 82.3 ± 15.5 78.9 ± 14.4 83.4 ± 19.3 80.9 ± 19.8 0.08
Hypertension (n = 626) 357 (57.0%) 90 (70.3%) 71 (55.5%) 67 (55.8%) 71 (54.2%) 58 (48.7%) <0.05
Diabetes (n = 626) 86 (13.7%) 21 (16.4%) 17 (13.3%) 17 (14.2%) 24 (18.3%) 7 (5.9%) 0.053
Dyslipidaemia (n = 625) 250 (40%) 51 (39.8%) 46 (35.9%) 55 (45.8%) 55 (42.3%) 43 (36.1%) 0.46
Family history of CAD (n = 597) 166 (27.8%) 40 (31.7%) 27 (21.8%) 37 (32.5%) 33 (27.3%) 29 (25.9%) 0.32
Smoking (n = 626)
Never 445 (71.1%) 93 (72.7%) 85 (66.4%) 88 (73.3%) 89 (67.9%) 90 (75.6%) 0.46
Former 95 (15.2%) 15 (11.7%) 26 (20.3%) 14 (11.7%) 26 (19.8%) 14 (11.8%) 0.08
Current 86 (13.7%) 20 (15.6%) 17 (13.3%) 18 (15%) 16 (12.2%) 15 (12.6%) 0.92
Important medical history (n = 809)
Myocardial infarction 51 (6.3%) 11 (6.6%) 8 (4.8%) 12 (7.5%) 13 (8.0%) 7 (4.5%) 0.6
CABG 19 (2.3%) 9 (5.4%) 2 (1.2%) 2 (1.3%) 4 (2.5%) 2 (1.3%) 0.052
PCI 78 (9.6%) 13 (7.8%) 18 (10.9%) 18 (11.3%) 20 (12.3%) 9 (5.7%) 0.23
Stroke 28 (3.5%) 6 (3.6%) 4 (2.4%) 10 (6.3%) 6 (3.7%) 2 (1.3%) 0.16
PVD 26 (3.2%) 5 (3.0%) 9 (5.5%) 3 (1.9%) 5 (3.1%) 4 (2.5%) 0.43
Malignancy 30 (3.7%) 5 (3.0%) 5 (3.0%) 7 (4.4%) 7 (4.3%) 6 (3.8%) 0.93
ECG findings
Heart rate (bpm) (n = 820) 68.6 ± 13.1 68.6 ± 12.8 68.5 ± 11.9 69.6 ± 12.8 68.6 ± 15.1 67.6 ± 12.5 0.74
Atrial fibrillation (n = 822) 20 (2.4%) 6 (3.6%) 2 (1.2%) 4 (2.5%) 5 (3.0%) 3 (1.9%) 0.64
Ventricular extrasystoles (≥ 10/min) 28 (3.4%) 4 (2.4%) 7 (4.2%) 7 (4.3%) 6 (3.6%) 4 (2.5%) 0.79
CMR parameters
LVEDVi (ml/m2 ) 79 ± 25.3 74.5 ± 27.8 75.5 ± 20.7 79.6 ± 24.4 80.3 ± 23.4 85.4 ± 28.2 <0.001
LVESVi (ml/m2 ) 36 ± 22.5 33.9 ± 25.0 32.8 ± 18.0 35.9 ± 20.8 37.4 ± 21.9 40.1 ± 25.6 <0.5
LVEF (%) 56.5 ± 11.6 56.9 ± 11.7 58.3 ± 10.3 56.5 ± 10.7 55.4 ± 13.4 55.2 ± 11.7 0.1
LVEF ≤ 35% 46 (5.6%) 9 (5.4) 5 (3.0) 8 (5.0) 12 (7.2) 12 (7.4) 0.39
LVMi (g/m2) 54.7 ± 17 59.0 ± 21.1 55.7 ± 17.0 54.1 ± 16.5 53.0 ± 13.8 51.4 ± 15.0 <0.01
bpm, beats per minute; CAD, coronary artery disease; EDV, end diastolic volume; EF, ejection fraction; ESV, end systolic volume; g, gram; i, indexed; LVM, LV mass; LV, left ventricle; m,
meter; min, minute; NC/C, non-compaction to compaction ratio. Numbers displayed are mean ± standard deviation or absolute number and percentage (please note, the denominator
varies depending on data completeness).
Atrial Fibrillation
Twenty (2.4%) participants had a history of atrial fibrillation.
There were no differences in the frequency of atrial fibrillation
among quintiles of maximal NC/C (p= 0.16) (Table 1).
Major Adverse Cardiovascular Events (MACE)
MACE was defined as the composite of all-cause mortality (n =
10), severe heart failure (n = 24), and stroke (prevalent = 28,
incident = 1). Some participants had more than more of these
outcomes, overall, 57 (12.8%) individuals had at least oneMACE.
The extent of maximal NC/C expressed as a continuous variable
and in quintiles was not associated with frequency of MACE
(Table 3). Sensitivity analysis did not show associations between
other LV trabeculation extent measures and the frequency
of MACE.
SUBGROUP ANALYSIS OF INDIVIDUALS
WITHOUT IHD
The 569 individuals without IHD were younger (p < 0.01) and
more likely to be women (p < 0.05). They had lower prevalence
of diabetes (p< 0.0001) and hypertension (p< 0.05) (Table 4). A
greater proportion of individuals in this cohort had NC/C >2.3
compared to the whole cohort (19.2 vs. 17.2%). However, the
mean maximal NC/C was comparable to the whole cohort at 1.82
± 0.7. There was greater mortality risk in individuals without
IHD, with 8 of the 10 observed deaths occurring in this group.
The overall MACEwas lower than the whole cohort (n= 35, 9.6%
vs. n = 57, 12.8%). There was no association between maximal
NC/C and mortality (OR 1.19, 95% CI: 0.39–2.62, p = 0.72) or
MACE (OR 0.65, 95% CI: 0.34–1.15, p = 0.17). The number
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TABLE 2 | Predictors of mortality in the EuroCMR Registry.
Odds ratio p-value Hazard ratio p-value
Baseline demographics and cardiovascular risk factors
Age per year 1.02 (0.97–1.08) 0.38 1.02 (0.97–1.08) 0.38
Females 1.09 (0.27–3.87) 0.89 1.08 (0.3–3.8) 0.91
Body mass index per kg/m2 1.01 (0.89–1.07) 0.85 1.01 (0.92–1.1) 0.83
Height per cm 1.03 (0.96–1.1) 0.42 1.03 (0.96–1.1) 0.43
Weight per kg 1.01 (0.98–1.04) 0.48 1.01 (0.98–1.04) 0.48
Hypertension 0.97 (0.21–5.0) 0.97 0.96 (0.22–4.3) 0.96
Diabetes 1.17 (0.06–7.01) 0.89 1.16 (0.14–9.63) 0.89
Dyslipidaemia 1.09 (0.21–5.01) 0.91 1.1 (0.25–4.9) 0.9
Smoking 1.0 (0.14–4.69) 0.99 1 (0.19–5.15) 1
CMR volume and function measures
LV end-diastolic volume index per ml/m2 1.02 (1–1.04) <0.05 1.02 (1.002–1.038) <0.05
LV end-systolic volume index per ml/m2 1.02 (1.002–1.04) <0.05 1.02 (1.005–1.036) <0.01
LV ejection fraction per% 0.94 (0.91–0.98) <0.01 0.94 (0.91–0.980) <0.001
LV mass index per g/m2 1.03 (1.01–1.05) <0.01 1.03 (1.01–1.05) <0.01
Late gadolinium enhancement 6.4 (1.79–25.35) <0.01 6.1 (1.7–21.8) <0.01
Maximal NC/C as a continuous variable
Maximal NC/C per 1 unit 1.39 (0.52–2.84) 0.44 1.38 (0.61–3.13) 0.44
Quintiles of maximal NC/C vs. 1
Quintile 2 No events 0.99 1
Quintile 3 2.1 (0.4–15.4) 0.4 2.04 (0.4–11.1) 0.41
Quintile 4 1.59 (0.3–12.2) 0.62 1.6 (0.3–9.4) 0.62
Quintile 5 0.59 (0.03–6.2) 0.67 0.58 (0.05–6.4) 0.66
Quintile 5 vs. remaining participants 0.51 (0.03–2.76) 0.53 0.5 (0.06–4.0) 0.52
Fulfilled Petersen’s LVNC criteria (NC/C C ≥ 2.3) 0.62 (0.03–3.37) 0.65 0.62 (0.08–4.87) 0.65
Number of segments with NC/C ≥ 2.3
1 No events 0.99 0.99
2 3.06 (0.16–17.8) 0.3 2.99 (0.38–23.6) 0.3
3 No events 0.99 1
4 No events 0.99 1
cm, centimeter; g, gram; kg, kilogram; m, meter; ml, milliliter; NC/C, non-compacted to compacted ratio.
TABLE 3 | Associations of maximal NC/C ratio with severe heart failure, stroke, and MACE.
Severe heart failure (NYHA III/IV) Stroke MACE
Odds ratio p-value Odds ratio p-value Odds ratio p-value
Maximal NC/C as a continuous variable
Maximal NC/C per 1 unit 0.65 (0.28–1.33) 0.28 0.82 (0.41–1.50) 0.56 0.81 (0.49–1.29) 0.39
Quintiles of maximal NC/C vs. quintile 1
Quintile 2 0.82 (0.2–3.2) 0.78 0.69 (0.17–2.5) 0.58 0.62 (0.24–1.55) 0.32
Quintile 3 1.99 (0.66–6.67) 0.23 1.85 (0.66–5.6) 0.25 1.57 (0.67–2.7) 0.26
Quintile 4 0.64 (0.13–2.69) 0.55 1.11 (0.34–3.7) 0.86 0.89 (0.46–2.0) 0.8
Quintile 5 0.71 (0.14–2.97) 0.64 0.6 (0.12–2.35) 0.48 0.62 (0.27–1.45) 0.33
Quintile 5 vs. remaining participants 0.64 (0.14–1.91) 0.48 0.52 (0.12–1.52) 0.29 0.62 (0.25–1.33) 0.26
Fulfilled Petersen’s LVNC criteria (NC/C ≥2.3) 0.49 (0.08–1.72) 0.35 0.41 (0.06–1.4) 0.23 0.52 (0.17–1.22) 0.17
Number of segments with NC/C ≥ 2.3
1 0.34 (0.02–1.66) 0.3 0.56 (0.09–1.96) 0.45 0.42 (0.1–1.21) 0.16
2 1.25 (0.07–6.63) 0.83 No events 0.99 1.03 (0.16–3.83) 0.97
3 No events 0.99 No events 0.99 No events 0.99
4 No events 0.99 No events 0.99 No events 0.99
MACE, major adverse cardiac events defined as severe heart failure, stroke, and death; NC/C, non compaction to compaction ratio; NYHA, New York Heart Association.
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TABLE 4 | Comparison of baseline data for the subgroup without IHD with the whole cohort.
All (n = 822) No IHD (n = 569) p-value
Baseline demographics and cardiovascular risk factors
Age (years) 59.4 ± 13.9 57.3 ± 14.3 <0.01
Females 306 (37.2%) 224 (39.4%) <0.05
Body mass index (kg/m2 ) 27.6 ± 5.9 27.7 ± 6.5 0.71
Height (cm) 172.2 ± 9.8 172.3 ± 9.9 0.90
Weight (kg) 81.8 ± 17.3 82.2 ± 18.2 0.75
Hypertension (n = 626) 357 (57.0%) 238 (54.1%) <0.05
Diabetes (n = 626) 86 (13.7%) 43 (9.8%) <0.0001
Dyslipidaemia (n = 625) 250 (40%) 159 (36.2%) <0.01
Family history of coronary disease (n = 597) 166 (27.8%) 114 (27.2%) 0.56
Smoking history (n = 626)
Never 445 (71.1%) 313 (71.1%) 0.90
Former 95 (15.2%) 67 (15.2%) 0.99
Current 86 (13.7%) 60 (13.6%) 0.87
Previous medical history (n = 809)
Myocardial infarction 51 (6.3%) 0 <0.0001
CABG 19 (2.3%) 0 <0.0001
PCI 78 (9.6%) 0 <0.0001
Stroke 28 (3.5%) 13 (2.3%) <0.01
PVD 26 (3.2%) 12 (2.1%) <0.01
Malignancy 30 (3.7%) 16 (2.8%) <0.05
ECG findings
Heart rate (bpm) (n = 820) 68.6 ± 13.1 68.9 ± 13.3 0.67
Atrial fibrillation (n=822) 20 (2.4%) 11 (1.9%) 0.24
Ventricular extrasystoles (≥ 10/min) 28 (3.4%) 21 (3.7%) 0.56
CMR parameters
LV end-diastolic volume index (ml/m2 ) 79.0 ± 25.3 78.3 ± 24.5 0.63
LV end-systolic volume index (ml/m2 ) 36.0 ± 22.5 34.9 ± 21.0 0.37
LV ejection fraction (%) 56.5 ± 11.6 57.3 ± 11.1 0.19
Severe LVSD (EF<35%) 46 (5.6%) 29 (5.1%) 0.54
LV mass index (g/m2) 54.7 ± 17 53.8 ± 17.2 0.37
Bpm, beats per minute; CABG, coronary artery bypass graft; cm, centimeter; g, gram; IHD, ischaemic heart disease; kg, kilogram; LV, left ventricle; m, meter; ml, milliliter; PCI,
percutaneous coronary intervention; PVD, peripheral vascular disease. Numbers displayed are mean ± standard deviation or absolute number and percentage (please note, the
denominator varies depending on data completeness).
of individual outcomes (other than all-cause mortality) was too
small in this subgroup for sufficiently powered statistical analysis.
DISCUSSION
Summary of Findings
In this multicenter multinational study of real-life patients
with clinical indication for CMR, we identified no association
between the extent of LV trabeculation and increased risk of
all-cause mortality, severe heart failure, stroke, atrial fibrillation,
or MACE composed of all these parameters. The same result
was observed with subgroup analysis of individuals without IHD
and with stratified analysis using the threshold of NC/C >2.3.
Women and younger individuals had greater magnitudes of
LV trabeculation, as did those with larger cavity volumes and
lower LVEF.
Strengths and Limitations
Whilst the inclusion of consecutive real-life clinical patients is
a strength of this study, analysis of individuals with relevant
symptoms in a more selective manner may provide more
meaningful context for interpretation of clinical significance
of LV trabeculation. However, this approach would introduce
ascertainment bias, which has hampered previous studies with
highly selective cohorts. We only used one method to quantify
trabeculation extent. However, whilst other methods exist
(22), method of measurement does not appear to result in
important differences (23). Substantial number of participants
had missing data for the mortality outcome (n = 292),
we limited our analysis to individuals with an explicitly
documented mortality outcome (dead/alive). Of course, there
is still potential for bias, e.g., relating to excess deaths in
the missing cohort, however, we believe our approach is the
method with least potential for bias within the limitations
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of the information available. Our observations reflect short-
term risk with an average follow-up period of just over 12
months; we cannot exclude longer term prognostic significance
of LV trabeculation.
Comparison With Existing Literature
The proportion of individuals in our study with NC/C >2.3
in at least one segment was high (17%, n = 142), however
this did not translate to an exaggerated rate of adverse events.
Similar prevalence of LV hyper-trabeculation has been reported
in multiple studies of healthy cohorts with no association to
poor outcomes (9, 11). Notably, analysis of 2,742 asymptomatic
individuals free of cardiovascular disease from the multi-
ethnic study of atherosclerosis (MESA) with 9.5 years follow-
up showed no association between adverse cardiac remodeling
and LV trabeculation extent (10). Amzulescu et al. report
more frequent observation of LV hyper-trabeculation in a
cohort of 162 dilated cardiomyopathy patients (NC/C ≥ 2.3
in 36%). However, clinical outcomes were related to left
and right ventricular remodeling and the presence of late
gadolinium enhancement (LGE), and not trabeculation extent
(16). High rates of excess LV trabeculation were also reported
in a study of 101 healthy pregnant women (25.4%), with
resolution in 73% after childbirth (12). Studies of healthy
athletes also report higher rates of excess LV trabeculation
with no clear prognostic relevance (13). These cohorts have
in common LV dilatation as part of their LV remodeling
phenotype. It is conceivable, that increased cavity size allows
better visualization and delineation of trabeculae, thereby
introducing a systematic measurement error toward over-
estimation. Indeed, we also observed greater measures of LV
trabeculation in individuals with larger LV volumes. Systematic
over-estimation of the trabecular component seems more likely
than genuine increased trabeculation in these populations
or de-novo appearance and spontaneous disappearance of
LV trabeculae in pregnancy and post-partum as had been
suggested (12).
Ivanov et al. present the only other study, aside from
ours, assessing the significance of LV trabeculation extent in
a real-life clinical setting (15). Consistent with our findings,
they report no association between LV trabeculation extent
and adverse clinical events (death, ischemic stroke, ventricular
tachycardia/ventricular fibrillation, heart failure hospitalization)
in 700 consecutive patients undergoing clinical CMR in a
single centre over 7 years of prospective follow-up. Interestingly,
a multicenter Italian study with a more selective population
of individuals with a diagnosis of LVNC based on clinical
and imaging criteria also reports no prognostic value of LV
trabeculation extent above and beyond LV dilation, LV systolic
dysfunction, and presence of LGE over 2 years of prospective
follow-up (17).
Thus, there is accumulating evidence from multiple
clinical studies, with a variety of study designs, in different
populations disputing the clinical significance of LV hyper-
trabeculation. Furthermore, the genetic and embryologic
origins of LVNC have been questioned. Although several
genetic links to LVNC have been established, there is significant
overlap with other cardiomyopathies and no single gene
has been reliably and specifically linked to LVNC (24).
Additionally, the embryologic origins of LVNC have been
disputed with recent studies contesting the existence of
an in-utero “myocardial compaction” phase (24–26). The
intra-uterine period is a hugely important phase of cardiac
development, during which the cardiovascular system is
exposed to marked haemodynamic change and detectable
changes in adult cardiac morphology have been demonstrated
with alterations in the intra-uterine environment (27). It
is conceivable that the observed differences in patterns
of LV trabeculation are an epiphenomenon reflecting the
haemodynamic changes, rates of myocardial growth, and
myocardial differentiation in-utero rather than a distinct
genetic cardiomyopathy.
Whilst initially presented as a rare genetic cardiomyopathy
with poor outcomes, growing evidence from a number of
sources in different populations shows high prevalence of LV
hyper-trabeculation by imaging criteria with no evidence
of associated prognostic significance. Furthermore, the
genetic and embryologic evidence for the etiology of LVNC
are equivocal, with the absence of a clear gene-phenotype
link and lack of evidence for an embryologic myocardial
compaction phase. It seems increasingly likely that the
initial reported poor outcomes relating to LVNC were the
biased results of highly selective tertiary centre cohorts.
It is clear from the available evidence, that the current
imaging criteria for quantification of LV trabeculation
are too broad, capturing high proportions of individuals
with no underlying cardiac disease and no increased risk of
adverse events.
CONCLUSION
This study adds to the growing evidence that LV hyper-
trabeculation in isolation is not a predictor of risk and does
not mandate further investigation or follow-up. In cases, where
there is uncertainty regarding the existence of LVNC as a distinct
cardiomyopathy, physicians should take a holistic approach and
exert caution in making this diagnosis.
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